A double-blind clinical trial involving 120 patients with chronic schistosomiasis was carried out to compare the tolerability and efficacy of praziquantel and oxamniquine. The patients were randomly allocated into two groups. One was treated with praziquantel, 55 mg/kg of body weight CBWT), and the other one with oxamniquine, 15mg/kg bwt, administered in a single oral dose. The diagnosis and the parasitological follow-up was based on stool examinations by quantitative Kato-Katz method and on rectal biopsies. Side-effects -mainly dizziness, sleepness, abdominal distress, headache, nausea and diarrhea -were observed in 87% of the cases. Their incidence, intensity and duration were similar for both drugs but abdominal pain was significantly more frequent after praziquantel intake and severe dizziness was more commonly reported after oxamniquine. A significant increase of alanine-aminotransferase and y-glutamyltransferase was found with the latter drug and of total bilirubin with the former one. A total of 48 patients treated with praziquantel and 46 with oxamniquine completed with negative findings the required three post-treatment parasitological controls -three slides of each stool sample on the first, third and sixth month. The achieved cure rates were 79.2% and 84.8%, respectively, a difference without statistical significance. The non-cured cases showed a mean reduction in the number of eggs per gram of feces of 93.5% after praziquantel and of 84.1% after oxamniquine. This diference also was not significant. Five patients retreated with praziquantel were cured but only one out of three treated a second time with oxamniquine. These findings show that both drugs -despite their different chemical structures, pharmacological properties and mechanisms-of-action -induce similar sid&effects as well as a comparable therapeutical efficacy, in agreement with the results reported from analogous investigations.
INTRODUCTION
Chemotherapy in a single-dose schedule with the treatment of schistosomiasis mansoni». The potent drugs represented a breakthrought in first one was hycanthone, mainly administered by intramuscular route. Unfortunately, some cases of fatal toxic hepatitis *- 6 and drug re sistance 1^ were reported.
With the appearance of oxamniquine, hycanthone was rapidly withdrawn and it is no longer available in Brazil.
Over the last 10 years oxamniquine, a tetra hydroquinoline derivative, has been extensively used in our country, not only for individual treatment 28 but also as mass treatment 13 . In teresting enough this drug showed a greater efficacy against the Brazilian strain of Schisto soma mansoni than against the African strain 18 .
Despite its good tolerability oxamniquine may cause unwanted side-effects such as: severe dizziness, mostly in fasting conditions 28 ; neu rological disturbances in animals 15 and in hu mans 18 and occasionaly seizures 2 « 2 5 . Moreover, elevation of serum activity of aminotransfera ses a few days after treatment has been report ed in some patients with schistosomiasis 28 . On the other hand, cases of resistance to oxamni quine have been published ] W, and finally its efficacy in humans was recently disputed in our country 8 .
These findings justified further investiga tions with new antischistosome agents. Prazi quantel, a heterocyclic pyrazino-isoquinoline compound, is a relatively new drug jointly de veloped by E. Merck -Darmstadt and Bayer AG -Leverkusen. It was found to be parti cularly active against Schistosoma mansoni, S. haematobium and S. japonicum, the three main species pathogenic to man w^A* 2 .
In order to compare the tolerability and efficacy of praziquantel and oxamniquine, this double-blind clinical trial was carried out.
MATERIAL AND METHODS
One hundred and twenty patients with chronic intestinal or hepato-intestinal forms of schistosomiasis were included in the trial.
The selection of patients was based on age (older than 14 years), clinical form (hepatosplenic cases were not included) and worm burden established by three pre-treatment ex cretai egg counts according to Kato-Katz me thod 17 . Patients with associated acute and/or serious diseases and those who were pregnant or who have been treated within the previous 6 months with any anti-schistosomal drug were excluded.
After parasitological diagnosis, the 120 pa tients were randomly allocated into two groups having an equal number of cases. One received praziquantel 55 mg/kg bwt and the other group oxamniquine 15 mg/kg bwt. Both drugs were given in a single oral dose in accordance with a double-blind technique.
Evaluation of symptoms and physical exa mination were performed on the same day and 24 to 48 hours after the drug administration. Report of side-effects was attained through the spontaneous information of the patients.
Blood was collected just before, 24 to 48 hours and on the 7th. day after treatment. The following tests were accomplished: alanineaminotransferase (ALT); aspartate-aminotrans ferase (AST); gammaglutamyl-transferase; and bilirubin.
One patient was not included in the eva luation of tolerance and toxicity as he was. inadvertently treated with oxamniquine at the beginning of an assymptomatic viral hepatitis. The evolution was uneventful.
The assessment of drug efficacy was based on three slides of each stool sample obtained prior to as well as one, three and six months after tretment 21 . In 73 out of 77 patients with negative stool examinations up to the sixth month, 4 to 6 biopsies were taken from the valves of Houston during rectoscopy, always performed by the same investigator.
Patients with less than three negative posttreatment parasitological controls were not in cluded in the assessment of efficacy but all ca ses who eliminated viable eggs in any stool examination from the first month on after treat ment were considered as noncured; whenever feasible they were retreated with the same drug. The shortest period between both treatments was four months.
For the statistical analysis u& of side-effects tables of contingency 2x3 were constructed, and the hypothesis of homogeneity between the two groups was tested by the Pearson's statistic. A "one-sample profile analysis" was utilized to evaluate the biochemical data; for comparing the therapeutical efficacy it was applied the chi-square test and the Mann-Whithney test to confront the reduction of eggs eliminated by the non-cured cases. Calculations were done by using the software Statistical Analysis System.
RESULTS

Clinical and parasitologlcal findings
Sex, age, body-weight and egg counts from patients of the two groups were compared and no significant difference (p > 0.05) was found (Table I ). All but three patients had more than 100 S. mansoni eggs per gram of stools.
Tolerabillty
Side-effects following the administration •of praziquantel or oxamniquine were observed in 53 out of 60 patients (88.3%) and in 51 out of 59 (86.4%), respectively. The main complaints were dizziness, sleepness, abdominal pain or •disconfort, headache, nausea and diarrhea, (Ta ble II). Abdominal pain was significantly more frequent (p < 0.001) after praziquantel intake. A severe degree of dizziness occurred in 13 out •of 59 cases (22.0%) after oxamniquine, and in 5 out of 60 (8.3%) after praziquantel but this difference was not significant (p > 0.1), Most of the symptoms disappeared without additio nal medication within a few hours.
Biochemical data
Table III displays the data obtained before T 0 , two days (T 2 ) and 7 days (T 7 ) after chemo therapy.
According to Wilks (W) and Fisher-Snedecor's (F) statistics, significant changes were observed with alanine-aminotransferase (p < 0.05) and gammaglutamyltransferase (p < 0.01> after oxamniquine and with total bilirubin (p < 0.05) after praziquantel. In order to study the influence of time on these changes, the abovementioned liver function tests were further submitted to statistical analysis with the same methods. The results are shown in Table IV . A significant difference was observed between T 0 and T 7 and T 2 and T 7 for ALT and GGT after oxamniquine. For TB after praziquantel a significant difference was observed between T 2 and T 7 .
Efficacy
The parasitological follow-up examinations were completed in 94 patients. In the prazi quantel group 38 out of 48 (79.2%) were con sidered as cured; and in the oxamniquine group 39 out of 46 (84.8%). The difference was not statistically significant (p > 0.1).
Rectal mucosa biopsies in 73 out of 77 patients with three negative stool examinations did not show viable eggs.
Considering the non-cured cases, except lor one who received oxamniquine, all of them had a marked decrease in the mean number of eggs eliminated per gram of feces. The average reduction after praziquantel was 93.5% and after oxamniquine 84.1% (Table V) , a diffe rence without statistical significance (p > 0.1).
Six out of the non-cured patients with praziquantel were treated again with the same drug. Five were followed up for six months and all were considered as cured.
Retreatment with oxamniquine was carried out in four out of seven non-cured patients. Three completed the follow-up and only one was cured. A non-cured case was retreated once more but with praziquantel achieving parasitological negativation.
DISCUSSION
These data show that praziquantel and oxamniquine produce similar side-effects, des pite their different chemical structures and pharmacological properties. Only abdominal pain was more frequently observed with pra ziquantel. Most of the post-chemotherapy symp toms, although being frequent, were of slight or moderate intensity and did not require symp tomatic medication.
The serum enzymatic changes observed after oxamniquine intake deserve some com ments. It is a well-known fact that following chemotherapy there is a worm shift from the terminal mesenteric veins to the liver. Thus, the significant elevation of alanine-aminotrans ferase and of gammaglutamyltransferase found with oxamniquine might be due to worm em bolization. As a matter of fact, an experimental study in infected and non-infected mice, un dertaken in our laboratories has demonstrated that oxamniquine leads to worm embolization, focal hepatic necrosis and a significant increase in serum aminotransferase activity in the in fected mice but no changes were seen in the control animals". The absence of serum énzi-matic alterations ^ and the elevation of serum total bilirubin after praziquantel remain to be elucidated. , " The results of retreatment are worth to be mentioned. Though the number of non-cured patients submitted twice to the same drug therapy is rather small, there -was a tendency for the appearance of resistant cases to oxamniquine and apparently such occurrence does not influence the sensitivity of S. mansoni to praziquantel 11 .
RESUMO Estudo clínico duplo cego comparando praziquantel com oxamniquine
Com objetivo de se compararem a tolerabilidade e eficácia do praziquantel e oxamniquine, procedeu-se a um estudo prospectivo duplo-cego envolvendo 120 pacientes com esquistossomose intestinal ou hepatintestinal.
Os pacientes foram randomizados em dois grupos. Um foi tratado com praziquantel, na dose de 55 mg/kg de peso, o outro com oxamniquine, 15 mg/kg de peso, sempre administrados em dose única por via oral. O diagnóstico e seguimento parasitológicos basearam-se ho exame de fazes peio método de Kate Katz. Em 73 de 77 casos negativos após tratamento, executaram-se biópsias retais.
Efeitos colaterais, principalmente tontura : sonolência, dores abdominais, cefaléia, náuseas e diarréia foram observados em 87% dos casos. Sua incidência, intensidade e duração foram semelhantes em ambos os grupos, mas a dor abdominal foi significativamente mais freqüen-te após praziquantel, havendo maior tendência para tontura intensa após oxamniquine. Observou-se aumento significante de alamina-amino¬ transferase e gama-glutamiltransferase após oxamniquine e de bilirrubina total após praziquantel.
Um total de 48 pacientes tratados com praziquantel e 46 com oxamniquine completaram os exames de controle até o sexto mês. As percentages de cura foram de 79,2% e de 84,8% respectivamente, diferença não significativa. Os pacientes não curados mostraram redução mé-dia do número de ovos de 93,5% e de 84,1%, diferença não significativa. Cinco pacientes retratados com praziquantel curaram-se, mas somente um de três retratados com oxamniquine.
Estes resultados mostram, que ambas as drogas-apesar de diferentes propriedades farmacológicas -provocam reações colaterais semelhantes e apresentam eficácia terapêutica comparável.
